Advances in sexually transmitted infections of the gastrointestinal tract

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 10, 2009, Pages 592-607

  Ng, Siew C ^a   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPICILLIN; BENZATHINE PENICILLIN; CEFTRIAXONE; CHEMOKINE RECEPTOR CCR5; COTRIMOXAZOLE; DOXYCYCLINE; METRONIDAZOLE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PROCAINE PENICILLIN; TETRACYCLINE; TRANSACTIVATOR PROTEIN;

ADAPTIVE IMMUNITY; AMEBIASIS; ANORECTAL DISEASE; CD4+ T LYMPHOCYTE; CHLAMYDIA; CHLAMYDIASIS; GASTROINTESTINAL INFECTION; GONORRHEA; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; LYMPHOGRANULOMA VENEREUM; MALE HOMOSEXUAL; MICROBIAL KINETICS; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SECONDARY SYPHILIS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SHIGELLOSIS; SIMIAN IMMUNODEFICIENCY VIRUS; SYPHILIS; T CELL DEPLETION; TH17 CELL; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HIV INFECTIONS; HIV-1; HUMANS; INTESTINAL MUCOSA; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, VIRAL;

EID: 70349987622     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.143     Document Type: Review

References (233)

1. Felman, Y. M. & Morrison, J. M. Examining the homosexual male for sexually transmitted diseases. JAMA 238, 2046-2047 (1977).
2. Kazal, H. L., Sohn, N., Carrasco, J. I., Robilotti, J. G. & Delaney, W. E. The gay bowel syndrome: clinico-pathologic correlation in 260 cases. Ann. Clin. Lab. Sci. 6, 184-192 (1976).
3. Weller, I. V. The gay bowel. Gut 26, 869-875 (1985).
4. Fleming, D. T. & Wasserheit, J. N. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex. Transm. Infect. 75, 3-17 (1999).
5. Benn, P. D. et al. Chlamydia trachomatis and Neisseria gonorrheae infection and the sexual behavior of men who have sex with men. Sex. Transm. Infect. 83, 106-112 (2007).
6. Elford, J., Bolding, G., Davis, M., Sherr, L. & Hart, G. Trends in sexual behavior among London homosexual men 1998-2003: implications for HIV prevention and sexual health promotion. Sex. Transm. Infect. 80, 451-454 (2004).
7. Schwarcz, S. K. et al. Characterization of sexually transmitted disease clinic patients with recent human immunodeficiency virus infection. J. Infect. Dis. 186, 1019-1022 (2002).
8. Regueiro, M. D. Diagnosis and treatment of ulcerative proctitis. J. Clin. Gastroenterol. 38, 733-740 (2004).
9. Davis, B. T., Thiim, M. & Zukerberg, L. R. Case records of the Massachusetts General Hospital. Case 2-2006: a 31-year-old, HIV-positive man with rectal pain. N. Engl. J. Med. 354, 284-289 (2006).
10. Davis, T. W. & Goldstone, S. E. Sexually transmitted infections as a cause of proctitis in men who have sex with men. Dis. Colon Rectum 52, 507-512 (2009).
11. Wexner, S. D. Sexually transmitted diseases of the colon, rectum and anus: the challenge of the nineties. Dis. Colon Rectum 33, 1048-1062 (1990).
12. Mimiaga, M. J. et al. Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. Sex. Transm. Dis. 35, 495-498 (2008).
13. Mimiaga, M. J. et al. Gonococcal, chlamydia, and syphilis infection positivity among MSM attending a large primary care clinic, Boston, 2003 to 2004. Sex. Transm. Dis. 36, 507-511 (2009).
14. Warkowski, K. A. & Berman S. M. Sexually transmitted diseases treatment guidelines, 2006, MMWR Recommendations and Reports August 4, 2006, 55 (RR 11), 1-94. CDC [online], http://www.cdc.gov/mmwr/ preview/mmwrhtml/rr5511a1.htm (2006).
15. Bryson, Y. J. et al. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N. Engl. J. Med. 308, 916-921 (1983).
16. Corey, L. The diagnosis and treatment of genital herpes. JAMA 248, 1041-1049 (1982).
17. Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
18. Gallo, R. C. et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220, 865-867 (1983).
19. Kotler, D. P., Gaetz, H. P., Lange, M., Klein, E. B. & Holt, P. R. Enteropathy associated with the acquired immunodeficiency syndrome. Ann. Intern. Med. 101, 421-428 (1984).
20. Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148-158 (2006).
21. Schacker, T., Collier, A. C., Hughes, J., Shea, T. & Corey, L. Clinical and epidemiologic features of primary HIV infection. Ann. Intern. Med. 125, 257-264 (1996).
22. Haase, A. T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5, 783-792 (2005).
23. Sharpstone, D. et al. Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhea. Gut 45, 70-76 (1999).
24. Kapembwa, M. S. et al. Altered small-intestinal permeability associated with diarrhea in human-immunodeficiency-virus-infected Caucasian and African subjects. Clin. Sci. (Lond.) 81, 327-334 (1991).
25. Bjarnason, I. et al. Intestinal inflammation, ileal structure and function in HIV. AIDS 10, 1385-1391 (1996).
26. Blanshard, C. & Gazzard, B. G. Natural history and prognosis of diarrhea of unknown cause in patients with acquired immunodeficiency syndrome (AIDS). Gut 36, 283-286 (1995).
27. Blanshard, C., Francis, N. & Gazzard, B. G. Investigation of chronic diarrhea in acquired immunodeficiency syndrome: a prospective study of 155 patients. Gut 39, 824-832 (1996).
28. Smith, P. D. et al. Intestinal infections in patients with the acquired immunodeficiency syndrome (AIDS): etiology and response to therapy. Ann. Intern. Med. 108, 328-333 (1988).
29. + T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques. Gastroenterology 116, 1115-1123 (1999).
30. Batman, P. A. et al. HIV enteropathy: crypt stem and transit cell hyperproliferation induces villous atrophy in HIV/ Microsporidia-infected jejunal mucosa. AIDS 21, 433-439 (2007).
31. Batman, P. A. et al. Jejunal enteropathy associated with human immunodeficiency virus infection: quantitative histology. J. Clin. Pathol. 42, 275-281 (1989).
32. Sharpstone, D. & Gazzard, B. Gastrointestinal manifestations of HIV infection. Lancet 348, 379-383 (1996).
33. Derouin, F. & Lagrange-Xelot, M. Treatment of parasitic diarrhea in HIV-infected patients. Expert Rev. Anti Infect. Ther. 6, 337-349 (2008).
34. Lewthwaite, P., Gill, G. V., Hart, C. A. & Beeching, N. J. Gastrointestinal parasites in the immunocompromised. Curr. Opin. Infect. Dis. 18, 427-435 (2005).
35. Mela, C. M. et al. Depletion of natural killer cells in the colonic lamina propria of viremic HIV-1-infected individuals. AIDS 21, 2177-2182 (2007).
36. Kosub, D. A. et al. γ/δ T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections. J. Virol. 82, 1155-1165 (2008).
37. Nilssen, D. E. et al. Intraepithelial γ/δ T cells in duodenal mucosa are related to the immune state and survival time in AIDS. J. Virol. 70, 3545-3550 (1996).
38. Martinelli, E. et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-α secretion in plasmacytoid dendritic cells. Proc. Natl Acad. Sci. USA 104, 3396-3401 (2007).
39. Mandl, J. N. et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14, 1077-1087 (2008).
40. Stagg, A. J., Kamm, M. A. & Knight, S. C. Intestinal dendritic cells increase T cell expression of α4β7 integrin. Eur. J. Immunol. 32, 1445-1454 (2002).
41. Mora, J. R. et al. Selective imprinting of guthoming T cells by Peyer's patch dendritic cells. Nature 424, 88-93 (2003).
42. + dendritic cells in the regulation of tissue-selective T cell homing. J. Exp. Med. 202, 1063-1073 (2005).
43. Butcher, E. C., Williams, M., Youngman, K., Rott, L. & Briskin, M. Lymphocyte trafficking and regional immunity. Adv. Immunol. 72, 209-253 (1999).
44. Zabel, B. A. et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J. Exp. Med. 190, 1241-1256 (1999).
45. Burns, R. C. et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 121, 1428-1436 (2001).
46. Goto, A., Arimura, Y., Shinomura, Y., Imai, K. & Hinoda, Y. Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflamm. Bowel. Dis. 12, 758-765 (2006).
47. Farkas, S. et al. Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int. J. Colorectal Dis. 21, 71-78 (2006).
48. Iwata, M. et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21, 527-538 (2004).
49. Johansson-Lindbom, B. et al. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J. Exp. Med. 198, 963-969 (2003).
50. + T cells up to 1 year after the initiation of highly active antiretroviral therapy for human immunodeficiency virus type 1 infection. J. Infect. Dis. 184, 93-97 (2001).
51. Hengel, R. L., Jones, B. M., Kennedy, M. S., Hubbard, M. R. & McDougal, J. S. Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans. J. Immunol. 163, 3539-3548 (1999).
52. Arthos, J. et al. HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9, 301-309 (2008).
53. Miao, Y. M. et al. Elevated mucosal addressin cell adhesion molecule-1 expression in acquired immunodeficiency syndrome is maintained during antiretroviral therapy by intestinal pathogens and coincides with increased duodenal CD4 T cell densities. J. Infect. Dis. 185, 1043-1050 (2002).
54. Smith, P. D., Meng, G., Salazar-Gonzalez, J. F. & Shaw, G. M. Macrophage HIV-1 infection and the gastrointestinal tract reservoir. J. Leukoc. Biol. 74, 642-649 (2003).
55. Janoff, E. N. & Smith, P. D. Emerging concepts in gastrointestinal aspects of HIV-1 pathogenesis and management. Gastroenterology 120, 607-621 (2001).
56. + T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998).
57. + T cells in multiple tissues during acute SIV infection. Nature 434, 1093-1097 (2005).
58. + T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J. Virol. 81, 599-612 (2007).
59. + T cells. Nature 434, 1148-1152 (2005).
60. + memory T cells in rapidly progressive simian immunodeficiency virus infection. J. Exp. Med. 200, 1299-1314 (2004).
61. Canani, R. B. et al. Effects of HIV-1 Tat protein on ion secretion and on cell proliferation in human intestinal epithelial cells. Gastroenterology 124, 368-376 (2003).
62. Dandekar, S. Pathogenesis of HIV in the gastrointestinal tract. Curr. HIV/AIDS Rep. 4, 10-15 (2007).
63. Canani, R. B. et al. Inhibitory effect of HIV-1 Tat protein on the sodium-d-glucose symporter of human intestinal epithelial cells. AIDS 20, 5-10 (2006).
64. Cossarizza, A. Apoptosis and HIV infection: about molecules and genes. Curr. Pharm. Des. 14, 237-244 (2008).
65. Veazey, R. S. & Lackner, A. A. HIV swiftly guts the immune system. Nat. Med. 11, 469-470 (2005).
66. Brenchley, J. M., Price, D. A. & Douek, D. C. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7, 235-239 (2006).
67. Schneider, T. et al. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea and Wasting Syndrome Study Group. Gut 37, 524-529 (1995).
68. + effector memory insufficiency and overt disease in chronic SIV infection. J. Exp. Med. 204, 2171-2185 (2007).
69. Giorgi, J. V. et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine co-receptor usage. J. Infect. Dis. 179, 859-870 (1999).
70. Rodriguez, B. et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 296, 1498-1506 (2006).
71. Caradonna, L. et al. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J. Endotoxin Res. 6, 205-214 (2000).
72. Cooke, K. R., Olkiewicz, K., Erickson, N. & Ferrara, J. L. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J. Endotoxin Res. 8, 441-448 (2002).
73. Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371 (2006).
74. Gordon, S. N. et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J. Immunol. 179, 3026-3034 (2007).
75. + T cells is not predictive of simian immunodeficiency virus virulence. J. Immunol. 179, 3035-3046 (2007).
76. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197, 126-133 (2008).
77. Derdeyn, C. A. & Silvestri, G. Viral and host factors in the pathogenesis of HIV infection. Curr. Opin. Immunol. 17, 366-373 (2005).
78. Hazenberg, M. D. et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17, 1881-1888 (2003).
79. George, M. D., Sankaran, S., Reay, E., Gelli, A. C. & Dandekar, S. High-throughput gene expression profiling indicates dysregulation of intestinal cell cycle mediators and growth factors during primary simian immunodeficiency virus infection. Virology 312, 84-94 (2003).
80. Sankaran, S. et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc. Natl Acad. Sci. USA 102, 9860-9865 (2005).
81. Li, Q. et al. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J. Infect. Dis. 197, 420-429 (2008).
82. Keating, J. et al. Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhea. Gut 37, 623-629 (1995).
83. Stockmann, M. et al. Mechanisms of epithelial barrier impairment in HIV infection. Ann. NY Acad. Sci. 915, 293-303 (2000).
84. Stockmann, M. et al. Duodenal biopsies of HIV-infected patients with diarrhea exhibit epithelial barrier defects but no active secretion. AIDS 12, 43-51 (1998).
85. Greenson, J. K., Belitsos, P. C., Yardley, J. H. & Bartlett, J. G. AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea. Ann. Intern. Med. 114, 366-372 (1991).
86. Schmitz, H. et al. Supernatants of HIV-infected immune cells affect the barrier function of human HT-29/B6 intestinal epithelial cells. AIDS 16, 983-991 (2002).
87. Zeitz, M. et al. HIV/SIV enteropathy. Ann. NY Acad. Sci. 859, 139-148 (1998).
88. Adams, R. B., Planchon, S. M. & Roche, J. K. IFN-γ modulation of epithelial barrier function: time course, reversibility, and site of cytokine binding. J. Immunol. 150, 2356-2363 (1993).
89. Heller, F. et al. Interleukin-13 is the key effector TH2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550-564 (2005).
90. Gitter, A. H., Bendfeldt, K., Schulzke, J. D. & Fromm, M. Leaks in the epithelial barrier caused by spontaneous and TNF-α-induced single-cell apoptosis. FASEB J. 14, 1749-1753 (2000).
91. Fish, S. M., Proujansky, R. & Reenstra, W. W. Synergistic effects of interferon γ and tumor necrosis factor α on T84 cell function. Gut 45, 191-198 (1999).
92. Bruewer, M. et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171, 6164-6172 (2003).
93. Epple, H. J. et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 58, 220-227 (2009).
94. Schulzke, J. D. et al. Disrupted barrier function through epithelial cell apoptosis. Ann. NY Acad. Sci. 1072, 288-299 (2006).
95. Zeissig, S. et al. Changes in expression and distribution of claudins 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56, 61-72 (2007).
96. Clark, E., Hoare, C., Tanianis-Hughes, J., Carlson, G. L. & Warhurst, G. Interferon γ induces translocation of commensal Escherichia coli across gut epithelial cells via a lipid-raft-mediated process. Gastroenterology 128, 1258-1267 (2005).
97. Clark, E. C. et al. Glutamine deprivation facilitates tumor necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate. Gut 52, 224-230 (2003).
98. Olsson, J. et al. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and β-chemokines. J. Infect. Dis. 182, 1625-1635 (2000).
99. McGowan, I. et al. Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J. Acquir. Immune Defic. Syndr. 37, 1228-1236 (2004).
100. Clayton, F. et al. Rectal mucosal pathology varies with human immunodeficiency virus antigen content and disease stage 17. Gastroenterology 103, 919-933 (1992).
101. Kotler, D. P., Reka, S. & Clayton, F. Intestinal mucosal inflammation associated with human immunodeficiency virus infection. Dig. Dis. Sci. 38, 1119-1127 (1993).
102. Zulu, I. et al. Cytokine activation is predictive of mortality in Zambian patients with AIDS-related diarrhea. BMC Infect. Dis. 8, 156 (2008).
103. REG cells. Curr. Opin. Immunol. 21, 274-280 (2009).
104. H17 and T regulatory cell populations in pathogenic infection of nonhuman primates [Abstract]. In 15th Conference on Retroviruses and Opportunistic Infections (eds Stevenson, M. & Mellors, J. W.) 117 (2008).
105. H17 CD4 cells in the gastrointestinal tract of HIV-infected individuals but not SIV-infected sooty mangabeys [Abstract]. In 15th Conference on Retroviruses and Opportunistic Infections (eds Stevenson, M. & Mellors, J. W. 115 (2008).
106. H17 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques [Abstract]. In 15th Conference on Retroviruses and Opportunistic Infections (eds Stevenson, M. & Mellors, J. W.) 116 (2008).
107. Raffatellu, M. et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat. Med. 14, 421-428 (2008).
108. Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141 (2005).
109. Brand, S. et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827-G838 (2006).
110. Schwartz, S., Beaulieu, J. F. & Ruemmele, F. M. Interleukin-17 is a potent immuno-modulator and regulator of normal human intestinal epithelial cell growth. Biochem. Biophys. Res. Commun. 337, 505-509 (2005).
111. Shacklett, B. L. Mucosal immunity to HIV: a review of recent literature. Curr. Opin. HIV AIDS 3, 541-547 (2008).
112. Paiardini, M., Frank, I., Pandrea, I., Apetrei, C. & Silvestri, G. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev. 10, 36-46 (2008).
113. Hamlyn, E. & Taylor, C. Sexually transmitted proctitis. Postgrad. Med. J. 82, 733-736 (2006).
114. Quinn, T. C. et al. The polymicrobial origin of intestinal infections in homosexual men. N. Engl. J. Med. 309, 576-582 (1983).
115. Marcus, U. et al. Shigellosis - a re-emerging sexually transmitted infection: outbreak in men having sex with men in Berlin. Int. J. STD AIDS 15, 533-537 (2004).
116. van der Bij, A. K. et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: a retrospective case-control study. Clin. Infect. Dis. 42, 186-194 (2006).
117. Macdonald, N. et al. Recent trends in diagnoses of HIV and other sexually transmitted infections in England and Wales among men who have sex with men. Sex. Transm. Infect. 80, 492-497 (2004).
118. Dougan, S., Evans, B. G. & Elford, J. Sexually transmitted infections in Western Europe among HIV-positive men who have sex with men. Sex. Transm. Dis. 34, 783-790 (2007).
119. Dougan, S. et al. Does the recent increase in HIV diagnoses among men who have sex with men in the UK reflect a rise in HIV incidence or increased uptake of HIV testing? Sex. Transm. Infect. 83, 120-125 (2007).
120. Fenton, K. A. & Lowndes, C. M. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex. Transm. Infect. 80, 255-263 (2004).
121. McMillan, A., van Voorst Vader, P. C., de Vries, H. J., International Union against Sexually Transmitted Infections-World Health Organization: the 2007 European Guideline (International Union against Sexually Transmitted Infections/World Health Organization) on the management of proctitis, proctocolitis and enteritis caused by sexually transmissible pathogens. Int. J. STD AIDS 18, 514-520 (2007).
122. British association for sexual health and HIV [online], http://www.bashh.org/ (2009).
123. Kent, C. K. et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin. Infect. Dis. 41, 67-74 (2005).
124. Schachter, J., Moncada, J., Liska, S., Shayevich, C. & Klausner, J. D. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex. Transm. Dis. 35, 637-642 (2008).
125. Gunn, R. A., O'Brien, C. J., Lee, M. A. & Gilchick, R. A. Gonorrhea screening among men who have sex with men: value of multiple anatomic site testing, San Diego, California, 1997-2003. Sex. Transm. Dis. 35, 845-848 (2008).
126. Klausner, J. D., Kohn, R. & Kent, C. Etiology of clinical proctitis among men who have sex with men. Clin. Infect. Dis. 38, 300-302 (2004).
127. Baker, R. W. & Peppercorn, M. A. Gastrointestinal ailments of homosexual men. Medicine (Baltimore) 61, 390-405 (1982).
128. William, D. C., Felman, Y. M. & Riccardi, N. B. The utility of anoscopy in the rapid diagnosis of symptomatic anorectal gonorrhea in men. Sex. Transm. Dis. 8, 16-17 (1981).
129. Schwarcz, S. K. et al. National surveillance of antimicrobial resistance in Neisseria gonorrheae. The Gonococcal Isolate Surveillance Project. JAMA 264, 1413-1417 (1990).
130. Martin, I. M., Hoffmann, S. & Ison, C. A. European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrheae in Western Europe. J. Antimicrob. Chemother. 58, 587-593 (2006).
131. Klein, E. J., Fisher, L. S., Chow, A. W. & Guze, L. B. Anorectal gonococcal infection. Ann. Intern. Med. 86, 340-346 (1977).
132. Craib, K. J. et al. Rectal gonorrhea as an independent risk factor for HIV infection in a cohort of homosexual men 1. Genitourin. Med. 71, 150-154 (1995).
133. Perine, P. L. & Stamm, W. E. Lymphogranuloma venereum. In Sexually Transmitted Diseases 3rd edn (eds Holmes, K. K. et al.) 423-432 (McGraw-Hill, New York, 1999).
134. Quinn, T. C. et al. Chlamydia trachomatis proctitis. N. Engl. J. Med. 305, 195-200 (1981).
135. Papagrigoriadis, S. & Rennie, J. A. Lymphogranuloma venereum as a cause of rectal strictures. Postgrad. Med. J. 74, 168-169 (1998).
136. Ward, H. et al. The prevalence of lymphogranuloma venereum (LGV) infection in men who have sex with men: results of a multicenter case finding study. Sex. Transm. Infect. 85, 173-175 (2009).
137. Schachter, J. Chlamydial infections (first of three parts). N. Engl. J. Med. 298, 428-435 (1978).
138. Schachter, J. Chlamydial infections (second of three parts). N. Engl. J. Med. 298, 490-495 (1978).
139. Nieuwenhuis, R. F. et al. Resurgence of lymphogranuloma venereum in western Europe: an outbreak of Chlamydia trachomatis serovar L2 proctitis in The Netherlands among men who have sex with men. Clin. Infect. Dis. 39, 996-1003 (2004).
140. Herida, M. et al. Rectal lymphogranuloma venereum surveillance in France 2004-2005. Euro. Surveill. 11, 155-156 (2006).
141. Ward, H. et al. Lymphogranuloma venereum in the United Kingdom. Clin. Infect. Dis. 44, 26-32 (2007).
142. Krosigk, A. et al. Dramatic increase in lymphogranuloma venereum among homosexual men in Hamburg [German]. J. Dtsch. Dermatol. Ges. 2, 676-680 (2004).
143. van de Laar, M. J., Koedijk, F. D., Gotz, H. M. & de Vries, H. J. A slow epidemic of LGV in The Netherlands in 2004 and 2005. Euro. Surveill. 11, 150-152 (2006).
144. Spaargaren, J., Fennema, H. S., Morre, S. A., de Vries, H. J. & Coutinho, R. A. New lymphogranuloma venereum Chlamydia trachomatis variant, Amsterdam. Emerg. Infect. Dis. 11, 1090-1092 (2005).
145. Berglund, T. et al. Two cases of lymphogranuloma venereum (LGV) in homosexual men in Stockholm. Euro. Surveill. 10, E050303 (2005).
146. Gebhardt, M. & Goldenberger, D. Lymphogranuloma venereum (LGV) serotype L2 in Switzerland, 2003-2005. Euro. Surveill. 10, E051222 (2005).
147. Vandenbruaene, M. et al. Lymphogranuloma venereum outbreak in men who have sex with men (MSM) in Belgium, January 2004 to July 2005. Euro. Surveill. 10, E050929 (2005).
148. Bremer, V., Meyer, T., Marcus, U. & Hamouda, O. Lymphogranuloma venereum emerging in men who have sex with men in Germany. Euro. Surveill. 11, 152-154 (2006).
149. Stark, D., van, H. S., Hillman, R., Harkness, J. & Marriott, D. Lymphogranuloma venereum in Australia: anorectal Chlamydia trachomatis serovar L2b in men who have sex with men. J. Clin. Microbiol. 45, 1029-1031 (2007).
150. Kropp, R. Y. & Wong, T. Emergence of lymphogranuloma venereum in Canada. CMAJ 172, 1674-1676 (2005).
151. Stary, G. & Stary, A. Lymphogranuloma venereum outbreak in Europe. J. Dtsch. Dermatol. Ges. 6, 935-940 (2008).
152. Stolte, I. G., Dukers, N. H., Geskus, R. B., Coutinho, R. A. & de Wit, J. B. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 18, 303-309 (2004).
153. Davaro, R. E. & Himlan, P. H. Immune restoration disorders following HAART. AIDS Read. 9, 167-169 (1999).
154. Cohen, M. S. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 351 (Suppl. 3), 5-7 (1998).
155. Meyer, T., Arndt, R., von, K. A. & Plettenberg, A. Repeated detection of lymphogranuloma venereum caused by Chlamydia trachomatis L2 in homosexual men in Hamburg. Sex. Transm. Infect. 81, 91-92 (2005).
156. Spaargaren, J. et al. Slow epidemic of lymphogranuloma venereum L2b strain. Emerg. Infect. Dis. 11, 1787-1788 (2005).
157. Stary, G. et al. New Chlamydia trachomatis L2 strains identified in a recent outbreak of lymphogranuloma venereum in Vienna, Austria. Sex. Transm. Dis. 35, 377-382 (2008).
158. van der Snoek, E. M., Ossewaarde, J. M., van der Meijden, W. I., Mulder, P. G. & Thio, H. B. The use of serological titers of IgA and IgG in (early) discrimination between rectal infection with non-lymphogranuloma venereum and lymphogranuloma venereum serovars of Chlamydia trachomatis. Sex. Transm. Infect. 83, 330-334 (2007).
159. Thomson, N. R. et al. Chlamydia trachomatis: genome sequence analysis of lymphogranuloma venereum isolates. Genome Res. 18, 161-171 (2008).
160. de Vries, H. J. et al. Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment. Clin. Infect. Dis. 48, e53-e56 (2009).
161. Solomon, L. et al. Epidemiology of recurrent genital herpes simplex virus types 1 and 2. Sex. Transm. Infect. 79, 456-459 (2003).
162. Goodell, S. E. et al. Herpes simplex virus proctitis in homosexual men. Clinical, sigmoidoscopic and histopathological features. N. Engl. J. Med. 308, 868-871 (1983).
163. Catterall, R. D. Sexually transmitted diseases of the anus and rectum. Clin. Gastroenterol. 4, 659-669 (1975).
164. Douglas, J. M. et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med. 310, 1551-1556 (1984).
165. Straus, S. E. et al. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N. Engl. J. Med. 310, 1545-1550 (1984).
166. Stamm, W. E. et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 260, 1429-1433 (1988).
167. Holmberg, S. D. et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 259, 1048-1050 (1988).
168. Anderson, J., Mindel, A., Tovey, S. J. & Williams, P. Primary and secondary syphilis, 20 years' experience. 3: Diagnosis, treatment, and follow up. Genitourin. Med. 65, 239-243 (1989).
169. Goh, B. T. Syphilis in adults. Sex. Transm. Infect. 81, 448-452 (2005).
170. French, P. et al. IUSTI: 2008 European guidelines on the management of syphilis. Int. J. STD AIDS 20, 300-309 (2009).
171. Kingston, M. et al. UK national guidelines on the management of syphilis, 2008. Int. J. STD AIDS 19, 729-740 (2008).
172. WHO. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. (WHO, Geneva, 2001).
173. Righarts, A. A., Simms, I., Wallace, L., Solomou, M. & Fenton, K. A. Syphilis surveillance and epidemiology in the United Kingdom. Euro. Surveill. 9, 21-25 (2004).
174. Simms, I. et al. The re-emergence of syphilis in the United Kingdom: the new epidemic phases. Sex. Transm. Dis. 32, 220-226 (2005).
175. Phipps, W., Kent, C. K., Kohn, R. & Klausner, J. D. Risk factors for repeat syphilis in men who have sex with men, San Francisco. Sex. Transm. Dis. 36, 331-335 (2009).
176. Cole, M. J., Chisholm, S., Palmer, H. M., Wallace, L. A. & Ison, C. A. Molecular epidemiology of syphilis in Scotland. Sex. Transm. Infect. (2009).
177. Walsh, J. A. Prevalence of Entamoeba histolytica infection. In Amebiasis: Human Infection by Entamoeba histolytica (ed. Ravdin, J. I.) 93-105 (Churchill Livingstone, New York, 1988).
178. Kao, S., Chiu, H. H. & Liu, Y. W. Education and imaging: gastrointestinal: amebic colitis. J. Gastroenterol. Hepatol. 24, 167 (2009).
179. Gatti, S., Cevini, C., Bruno, A., Novati, S. & Scaglia, M. Transmission of Entamoeba histolytica within a family complex. Trans. R. Soc. Trop. Med. Hyg. 89, 403-405 (1995).
180. Sexton, D. J. et al. Amebiasis in a mental institution: serologic and epidemiologic studies. Am. J. Epidemiol. 100, 414-423 (1974).
181. Ortega, H. B., Borchardt, K. A., Hamilton, R., Ortega, P. & Mahood, J. Enteric pathogenic protozoa in homosexual men from San Francisco. Sex. Transm. Dis. 11, 59-63 (1984).
182. Stanley, S. L. Jr. Amoebiasis. Lancet 361, 1025-1034 (2003).
183. Walsh, J. A. Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality. Rev. Infect. Dis. 8, 228-238 (1986).
184. Cuna-Soto, R., Maguire, J. H. & Wirth, D. F. Gender distribution in asymptomatic and invasive amebiasis. Am. J. Gastroenterol. 95, 1277-1283 (2000).
185. Reed, S. L., Wessel, D. W. & Davis, C. E. Entamoeba histolytica infection and AIDS. Am. J. Med. 90, 269-271 (1991).
186. Jessurun, J., Barron-Rodriguez, L. P., Fernandez-Tinoco, G. & Hernandez-Avila, M. The prevalence of invasive amebiasis is not increased in patients with AIDS. AIDS 6, 307-309 (1992).
187. Campos-Rodriguez, R. & Jarillo-Luna, A. The pathogenicity of Entamoeba histolytica is related to the capacity of evading innate immunity. Parasite Immunol. 27, 1-8 (2005).
188. Hung, C. C. et al. Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan. Arch. Intern. Med. 165, 409-415 (2005).
189. Hung, C. C. et al. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS. Negl. Trop. Dis. 2, e175 (2008).
190. Park, W. B. et al. Amebic liver abscess in HIV-infected patients, Republic of Korea. Emerg. Infect. Dis. 13, 516-517 (2007).
191. Singh, A., Houpt, E. & Petri, W. A. Rapid diagnosis of intestinal
192. Gonzales, M. L., Dans, L. F. & Martinez, E. G. Antiamoebic drugs for treating amoebic colitis. Cochrane. Database of Systematic Reviews Issue 2. Art. No.: CD006085. doi:10.1002/14651858.CD006085.pub2 (2009).
193. Lejeune, M., Rybicka, J. M. & Chadee, K. Recent discoveries in the pathogenesis and immune response toward Entamoeba histolytica. Future Microbiol. 4, 105-118 (2009).
194. Ravdin, J. I. & Guerrant, R. L. Role of adherence in cytopathogenic mechanisms of Entamoeba histolytica. Study with mammalian tissue culture cells and human erythrocytes. J. Clin. Invest. 68, 1305-1313 (1981).
195. Kammanadiminti, S. J., Mann, B. J., Dutil, L. & Chadee, K. Regulation of Toll-like receptor-2 expression by the Gal lectin of Entamoeba histolytica. FASEB J. 18, 155-157 (2004).
196. Arellano, J. et al. Increased frequency of HLA-DR3 and complotype SCO1 in Mexican mestizo children with amoebic abscess of the liver. Parasite Immunol. 18, 491-498 (1996).
197. Kotloff, K. L. et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 77, 651-666 (1999).
198. Dupont, H. L., Levine, M. M., Hornick, R. B. & Formal, S. B. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159, 1126-1128 (1989).
199. Chaisson, R. E. Infections due to encapsulated bacteria, Salmonella, Shigella, and Campylobacter. Infect. Dis. Clin. North Am. 2, 475-484 (1988).
200. Dritz, S. K. & Back, A. F. Letter: Shigella enteritis venereally transmitted. N. Engl. J. Med. 291, 1194 (1974).
201. Bader, M., Pedersen, A. H., Williams, R., Spearman, J. & Anderson, H. Venereal transmission of shigellosis in Seattle, King county. Sex. Transm. Dis. 4, 89-91 (1977).
202. Drusin, L. M., Genvert, G., Topf-Olstein, B. & Levy-Zombek, E. Shigellosis: another sexually transmitted disease? Br. J. Vener. Dis. 52, 348-350 (1976).
203. Aragon, T. J. et al. Case-control study of shigellosis in San Francisco: the role of sexual transmission and HIV infection. Clin. Infect. Dis. 44, 327-334 (2007).
204. Baer, J. T. et al. HIV infection as a risk factor for shigellosis. Emerg. Infect. Dis. 5, 820-823 (1999).
205. Daskalakis, D. C. & Blaser, M. J. Another perfect storm: Shigella, men who have sex with men, and HIV. Clin. Infect. Dis. 44, 335-337 (2007).
206. Nagler, J., Brown, M. & Soave, R. Blastocystis hominis in inflammatory bowel disease. J. Clin. Gastroenterol 16, 109-112 (1993).
207. Albrecht, H., Stellbrink, H. J., Koperski, K. & Greten, H. Blastocystis hominis in human immunodeficiency virus-related diarrhea. Scand. J. Gastroenterol. 30, 909-914 (1995).
208. Tan, K. S. Blastocystis in humans and animals: new insights using modern methodologies. Vet. Parasitol. 126, 121-144 (2004).
209. Weisheit, B., Bethke, B. & Stolte, M. Human intestinal spirochetosis: analysis of the symptoms of 209 patients. Scand. J. Gastroenterol. 42, 1422-1427 (2007).
210. Hoofnagle, J. H. Hepatitis C: the clinical spectrum of disease. Hepatology 26, 15S-20S (1997).
211. Gotz, H. M. et al. A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS 19, 969-974 (2005).
212. Danta, M. et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviors. AIDS 21, 983-991 (2007).
213. Serpaggi, J. et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 20, 233-240 (2006).
214. Browne, R. et al. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase? Sex. Transm. Infect. 80, 326-327 (2004).
215. Gambotti, L. et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004 Euro. Surveill. 10, 115-117 (2005).
216. Luetkemeyer, A. et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 41, 31-36 (2006).
217. Matthews, G. V., Hellard, M., Kaldor, J., Lloyd, A. & Dore, G. J. Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. AIDS 21, 2112-2113 (2007).
218. Danta, M. & Dusheiko, G. M. Acute HCV in HIV-positive individuals - a review. Curr. Pharm. Des. 14, 1690-1697 (2008).
219. Van de Laar, T. et al. Evidence of a large, international network of international HCV transmission in HIV-positive men who have sex with men. Gastroenterology 136, 1609-1617 (2009).
220. Danta, M. et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J. Infect. Dis. 197, 1558-1566 (2008).
221. Roe, B. & Hall, W. W. Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev. Mol. Med. 10, e30 (2008).
222. Brejt, N., Gilleece, Y. & Fisher, M. Acute hepatitis C: changing epidemiology and association with HIV infection. J. HIV Ther. 12, 3-6 (2007).
223. Graham, C. S. et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33, 562-569 (2001).
224. Greub, G. et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356, 1800-1805 (2000).
225. Nattermann, J. et al. The transforming growth factor-β high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C. AIDS 22, 1287-1292 (2008).
226. Nattermann, J. et al. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology 46, 1016-1025 (2007).
227. Larrea, E. et al. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies. Gut 55, 1188-1196 (2006).
228. Zhu, H., Shang, X., Terada, N. & Liu, C. STAT3 induces anti-hepatitis C viral activity in liver cells. Biochem. Biophys. Res. Commun. 324, 518-528 (2004).
229. Blindenbacher, A. et al. Expression of hepatitis C virus proteins inhibits interferon α signaling in the liver of transgenic mice. Gastroenterology 124, 1465-1475 (2003).
230. Geijtenbeek, T. B. et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597 (2000).
231. Amerongen, H. M. et al. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J. Acquir. Immune Defic. Syndr. 4, 760-765 (1991).
232. Bomsel, M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3, 42-47 (1997).
233. Meng, G. et al. Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat. Med. 8, 150-156 (2002).